Pharma mega-deals dont start with spreadsheets. They start with exclusivity.
If youve ever wondered why two companies can look at the same asset and arrive at wildly different valuations, the answer is often hiding in plain sight: the patchwork of lega…

Patent cliffs arent just a legal eventtheyre a pricing event.
If youre in pharma, biotech, payer strategy, or investment research, you already know the headlines: when exclusivity ends, generic and biosimilar competition can arrive fast, and prices c…

Post-Approval Isnt the Finish LineIts When Your Patent Strategy Gets Real
In pharma, the most expensive mistake is often the one made after approval.
Companies celebrate the launch, breathe out, and assume the hard part is over. But the regulatory and …

Post-approval is where the real IP game starts.
Most teams obsess over getting to approval—then quietly assume the hard part is over. It isn’t. In the months and years after launch, your product becomes a target: for generic challengers, for “evergre…

Pharma companies dont lose exclusivity because they missed a deadline. They lose it because they mismanaged the legal perimeter.
In todays generic and biosimilar landscape, defending patent exclusivity isnt just a regulatory exerciseits a litigation st…

From Humira to Keytruda: The Blueprint for Surviving the Composition of Matter Cliff
If you work in pharma, youve felt it: the moment the calendar starts to look like a countdown. Not because science suddenly stopsbut because patents do.
The compositio…

Pharmas patent cliff isnt just a cliff. Its a moving targetone that can be reshaped with a legal lever most investors barely model.
In a recent piece from DrugPatentWatch, the focus lands on method-of-use patentsoften described as the hidden lever that…

The Patent Dance, Decoded: How Biosimilar Developers Win (or Lose) Before Litigation Starts
In the biosimilar world, the fight rarely begins in a courtroom. It begins in a spreadsheet.
Before a single complaint is filedor a single expert report is exch…

Drug patent cliffs are no longer a later problem. Theyre a data problemsolvable now.
If youre still treating patent expiration and litigation risk as something you react to, youre already behind.
In the pharma world, the calendar is unforgiving: exclus…

Patent thickets arent just a legal inconveniencetheyre a market design problem. And if youre a pharma executive, investor, or in-house counsel, the real question isnt Can we clear patents? Its: Can we build a repeatable strategy that clears them faster…